Small and mid-cap biotech companies are primarily "capital consumers," making them highly sensitive to interest rates. As the Fed moves toward rate cuts, cheaper capital is expected to unlock significant spending on R&D pipelines and M&A activity, historically making biotech a top-performing sector after the first cut.

The current difficult funding environment is a natural correction following an anomalous 2020-2021 capital flood caused by near-zero interest rates. This boom led to unusual events like pre-clinical IPOs, followed by a predictable "valley of death" when rates rose. The model isn't broken; it's cyclical.

The market is pricing in overly aggressive Fed policy. As inflation fears subside, rate-sensitive sectors will benefit. Biotech, in particular, offers an attractive risk-reward setup as it historically performs well in falling rate environments and is currently bolstered by a strong M&A cycle.

The Fed lowering interest rates, as seen during COVID, makes capital cheap and pushes investors toward riskier assets like biotech to chase yield. This floods the market with capital, enabling even preclinical companies to go public—a trend that reverses sharply when rates rise.

While biotech is labeled "rate-sensitive," the sector's performance is driven by the overall direction and magnitude of interest rate changes, not small 25 basis point tweaks. The key concern is thematic shifts, like sustained 100+ basis point moves over a year, which fundamentally alter the macro environment for long-duration assets.

The long-dated nature of biotech investing makes it uniquely vulnerable to high interest rates. A 5% rate applied over a 10-15 year development cycle can compress valuation multiples by three to fourfold, drastically changing the financial landscape for the industry.

Unlike previous downturns blamed on high interest rates, analysts believe the biotech sector is now more mature, cash-flow positive, and fundamentally insulated from macro issues like oil prices, making it a more defensive investment.

The macro trend of rising bond yields creates a specific, acute risk for the AI sector. Many AI startups are funded by floating-rate private credit, and their debt service costs will explode as rates rise. This is compounded by high CapEx and an inability to scale revenues proportionally, creating a potential crash.

The past few years in biotech mirrored the tech dot-com bust, driven by fading post-COVID exuberance, interest rate hikes, and slower-than-hoped commercialization of new modalities like gene editing. This was caused by a confluence of factors, creating a tough environment for companies that raised capital during the peak.